IntroductionIntroduction

Structure of OspA (PDB entry 1FJ1)

Drag the structure with the mouse to rotate

Lyme disease has been affecting many individuals year around developing chronic arthritis, neurologic and cardiac abnormalities, and skin lesions (Burgdorferi, 1982). The bacterial vector, Borrelia burgdorferi is spread through the bite and feeding of ticks bringing initial severe skin lesions, erythema chronicum migrans within 10-12 weeks of infestation (Burgdorferi, 1982). Studies were first conducted through New Zealand white rabbits (Burgdorferi, 1982) through the use of indirect immunofluoresence.

Outer surface protein A, or OspA is found to inhibit bacterial transmission (Ding, 2000). Outer surface protein A, or OspA was found to initiate an immune response that contributed towards the development of Lyme disease vaccinations. It prevented the transmission of Borrelia burgdorferi, the causative bacterial agent of Lyme disease after the attachment of an infected tick (Ding, 2000). Once entered the host through the skin or blood stream, Borrelia burgdorferi downregulated and suppressed OspA to minimize all of the host’s immunogenic characteristics (Rupprecht, 2008). When OspA on the spirochete migrated to an inflammatory environment, it induced apoptosis on the bacteria through the activation of B-cells (Rupprecht, 2008). Only OspA positive in borrelia bacteria were unable to establish an infection compared to OspA negative bacteria successfully hosted in studies of mice (Rupprecht, 2008). OspA known as a potent stimulator of neutrophils was able to kill the pathogen and attract leukocytes allowing the release of proinflammatory cytokines in a host (Ruprecht, 2008) and avoid contracting Lyme disease as it affects the heart, joints, and nervous system (Rupprecht, 2008). The reactive LA-2 antibody was found to serve as an important epitope of Osp-A binding (Ding, 2000) towards developing vaccinations. The free state of the 3D model exposed the C-terminal where there were 49 residues from the “three loops” involved that significantly affected by LA-2 binding, through findings from NMR and crystallization (Ding, 2000).

About OspAAbout OspA

StructureStructure

Vaccination (La-2)Vaccination (La-2)

Side EffectsSide Effects

Comparing OspA , OspB , OspCComparing OspA , OspB , OspC

References:

Cite error: Invalid parameter in <ref> tag Cite error: Invalid parameter in <ref> tag

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Chris DiFiore, Yimei Miao, Kareema Roushdy, Michal Harel